Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, Inc. (APGE), sold 20,000 shares at $30.62 ($603K) on 2025-03-05, disclosed to the SEC on 2025-03-07.
Scheduled sale ($603k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $29.98 | 7,326 | $220K | 36.4% |
| 2 | $29.98 | 7,326 | $220K | 36.4% |
| 3 | $30.62 | 2,674 | $82K | 13.6% |
| 4 | $30.62 | 2,674 | $82K | 13.6% |
| Total | $30.15 avg | 20,000 | $603K | 100% |
| Filing → |
| SYRE | SELL | 2026-06-23 | $2.0M | — | Filing → |
| APGE | SELL | 2026-06-12 | $1.7M | — | Filing → |
| APGE | SELL | 2026-05-15 | $1.6M | — | Filing → |